Leerink Partnrs Increases Earnings Estimates for AxoGen

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - Investment analysts at Leerink Partnrs increased their FY2025 earnings per share (EPS) estimates for AxoGen in a note issued to investors on Monday, March 31st. Leerink Partnrs analyst M. Kratky now expects that the medical equipment provider will post earnings per share of ($0.11) for the year, up from their prior estimate of ($0.12). The consensus estimate for AxoGen's current full-year earnings is ($0.29) per share. Leerink Partnrs also issued estimates for AxoGen's FY2026 earnings at $0.04 EPS, FY2028 earnings at $0.23 EPS and FY2029 earnings at $0.34 EPS.

AXGN has been the topic of several other research reports. Canaccord Genuity Group boosted their price objective on shares of AxoGen from $22.00 to $26.00 and gave the stock a "buy" rating in a research note on Wednesday, February 26th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $24.00 target price on shares of AxoGen in a report on Wednesday, March 5th. Finally, Lake Street Capital started coverage on AxoGen in a research note on Monday, March 17th. They issued a "buy" rating and a $30.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, AxoGen currently has an average rating of "Buy" and a consensus price target of $22.60.

AxoGen Trading Down 4.8 %

NASDAQ AXGN traded down $0.82 during trading hours on Wednesday, reaching $16.22. The company's stock had a trading volume of 496,207 shares, compared to its average volume of 421,816. AxoGen has a 52 week low of $5.55 and a 52 week high of $21.00. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The stock has a market cap of $719.26 million, a P/E ratio of -50.69 and a beta of 1.02. The firm has a fifty day simple moving average of $18.16 and a 200-day simple moving average of $15.97.

Institutional Trading of AxoGen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Intech Investment Management LLC bought a new position in AxoGen in the third quarter worth approximately $173,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of AxoGen by 8.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 363,764 shares of the medical equipment provider's stock worth $5,100,000 after purchasing an additional 28,659 shares in the last quarter. FMR LLC grew its position in AxoGen by 743.1% in the 3rd quarter. FMR LLC now owns 178,957 shares of the medical equipment provider's stock valued at $2,509,000 after purchasing an additional 157,730 shares during the period. Quantbot Technologies LP bought a new stake in AxoGen during the 3rd quarter valued at $165,000. Finally, BNP Paribas Financial Markets raised its holdings in AxoGen by 238.6% during the third quarter. BNP Paribas Financial Markets now owns 12,284 shares of the medical equipment provider's stock worth $172,000 after buying an additional 8,656 shares during the last quarter. 80.29% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other AxoGen news, insider Erick Wayne Devinney sold 15,111 shares of AxoGen stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $17.50, for a total value of $264,442.50. Following the completion of the sale, the insider now directly owns 217,762 shares of the company's stock, valued at approximately $3,810,835. The trade was a 6.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Amy Mcbride Wendell sold 5,000 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $20.02, for a total transaction of $100,100.00. Following the transaction, the director now directly owns 97,899 shares in the company, valued at $1,959,937.98. This trade represents a 4.86 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.00% of the company's stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.